Leiden, Netherlands, Duesseldorf, Germany, July, 2026
In H1 2026, HAL and its team achieved several milestones:
- Commercial strategy delivers immediate results: already in H1 2026, revenue grew at a strong mid-single-digit organic rate, driven by broad-based growth across all markets and particularly strong performance in Germany, Europe’s largest AIT market.
- Landmark Phase III clinical trial: positive pivotal results for PURETHAL Mites PM50k, which demonstrated a 30% reduction in Total Combined Rhinitis Score versus placebo (p < 0.0001). Subject to regulatory approval in Germany and other geographies, PURETHAL Mites PM50k could offer a modern SCIT AIT option for patients with house dust mite allergy.
- Strategic partnership with Advanz Pharma: entered into a multi-year strategic collaboration spanning dermatology, pulmonology and allergology in Germany and Austria – expanding patient access to modern, cost-effective biosimilars while opening a new commercial growth avenue for HAL Allergy.
- Leadership team extended: Michael Kern (McKinsey & Co., Evotec) appointed as Chief Financial Officer (CFO), with responsibility for Finance, IT, Procurement and Business Development.
- Positive outlook, H2 growth trajectory supported: solid growth trajectory supported by continued commercial momentum based on strong prescriber relationships, new clinical outcomes and clinical R&D insights, a convincing product portfolio, and favorable market conditions. Additional R&D initiatives and portfolio enhancements are expected to drive further mid- to long-term growth.
“The first half of 2026 has been a defining period for HAL Allergy. We grew in line with our ambition to become a leading specialty biopharma company, delivered benchmark Phase III data, welcomed Advanz as a strong new biologics partner, and extended our leadership team. Building this momentum gives us confidence in the opportunities ahead,” said Dr. Philip Boehme, CEO of HAL Allergy Group.
About HAL Allergy
With more than 60 years of expertise, HAL Allergy (NL) is a privately owned, European specialty biopharma company dedicated to allergies and related diseases. Its foundation rests on proprietary allergen extraction, advanced allergoid technology, and GMP-certified manufacturing. On this basis, the company covers the full allergy care pathway – from diagnostics and allergen immunotherapy through to next-generation treatments. Supported by continued investment in R&D and a robust clinical pipeline, HAL Allergy aims to expand beyond allergy into adjacent disease areas, leveraging its expertise to transform the lives of a broad population of patients.
Media Contact
Heike Milan
HAL Allergie GmbH
Phone: +49 (0)211 97765 56
Email: hmilan@hal-allergy.com
HAL Allergy – Medical Information
Phone: +49 (0)211 97765 70
Email: medwiss@hal-allergy.com